Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Fatigue01:21

Fatigue

1.2K
Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fosinopril: HIV-Associated Nephropathy (HIVAN).

Hospital pharmacy·2024
Same author

Idarucizumab.

Hospital pharmacy·2024
Same author

Fentanyl Iontophoretic Transdermal System.

Hospital pharmacy·2024
Same author

Fifty Years of Publication: Hospital Pharmacy Anniversary.

Hospital pharmacy·2024
Same author

Rolapitant.

Hospital pharmacy·2024
Same author

Zafirlukast: Chronic Urticaria.

Hospital pharmacy·2016

Related Experiment Video

Updated: Apr 19, 2026

The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model
05:38

The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model

Published on: April 12, 2024

662

Amantadine: multiple sclerosis-related fatigue.

Joyce A Generali1, Dennis J Cada2

  • 1Editor-in-Chief, Hospital Pharmacy , and Clinical Professor, Emeritus, Department of Pharmacy Practice, University of Kansas, School of Pharmacy, Kansas City/Lawrence , Kansas ,

Hospital Pharmacy
|December 6, 2014
PubMed
Summary

This guide helps healthcare professionals quickly find and evaluate literature on unapproved drug uses (off-label drug uses). It supports rational patient care decisions by providing access to published studies and comprehensive references.

More Related Videos

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

20.6K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.3K

Related Experiment Videos

Last Updated: Apr 19, 2026

The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model
05:38

The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model

Published on: April 12, 2024

662
The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

20.6K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.3K

Area of Science:

  • Pharmacy
  • Pharmacology
  • Drug Utilization

Background:

  • Off-label drug use refers to prescribing medications for conditions not approved by the US Food and Drug Administration (FDA).
  • Practitioners require reliable resources to navigate the complexities of unapproved drug indications.
  • Existing literature on off-label drug uses can be fragmented and challenging to access.

Purpose of the Study:

  • To introduce a practitioner-oriented resource, Off-Label Drug Facts, for information on specific unapproved drug uses.
  • To enable healthcare professionals to efficiently identify and assess published studies on off-label drug applications.
  • To support evidence-based decision-making in patient care scenarios involving off-label drug use.

Main Methods:

  • Extraction of relevant content from the Off-Label Drug Facts publication.
  • Compilation of a guide focused on literature regarding off-label drug uses.
  • Inclusion of references to direct readers to comprehensive literature for further information.

Main Results:

  • Provides a structured approach to identifying published studies on off-label drug uses.
  • Facilitates the determination of the rationality of specific off-label uses in clinical practice.
  • Offers a pathway to comprehensive literature review for informed patient care decisions.

Conclusions:

  • Off-Label Drug Facts serves as a valuable tool for clinicians managing patients with off-label drug use.
  • The resource enhances the ability of healthcare professionals to make informed decisions regarding unapproved drug indications.
  • Access to curated literature supports rational and evidence-based patient care.